Day One BiopharmaceuticalsDAWN 12 EBITDA Margin % is -49.26% as of Dec. 2025. GuruFocus rates DAWN with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 945 Biotechnology companies, Day One Biopharmaceuticals ranks worse than 51.11% on this metric.
Day One Biopharmaceuticals (NAS:DAWN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Day One Biopharmaceuticals EBITDA Margin % Related Terms
Day One Biopharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DAWN vs TYRA, DFTX, MLYS: EBITDA Margin % Comparison
For the Biotechnology subindustry, Day One Biopharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Day One Biopharmaceuticals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Day One Biopharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Day One Biopharmaceuticals (DAWN) has a EBITDA Margin % of -49.26% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Day One Biopharmaceuticals and its competitors. According to the industry distribution chart, Day One Biopharmaceuticals ranks #483 out of 945 companies in the Biotechnology industry, placing it in the top 51.1%.
Is Day One Biopharmaceuticals' EBITDA Margin % too high?
Day One Biopharmaceuticals' current EBITDA Margin % is -49.26%. Based on the distribution chart, Day One Biopharmaceuticals ranks #483 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Day One Biopharmaceuticals' EBITDA Margin % compare to TYRA and DFTX?
According to the Biotechnology industry distribution chart, Day One Biopharmaceuticals ranks #483 out of 945 companies for EBITDA Margin %. This places Day One Biopharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Day One Biopharmaceuticals and its competitors. Day One Biopharmaceuticals's current EBITDA Margin % is -49.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Day One Biopharmaceuticals stock overvalued right now?
Day One Biopharmaceuticals (DAWN) has a current EBITDA Margin % of -49.26%. The current EBITDA Margin % is -49.26%. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current EBITDA Margin % is -49.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score
Get the complete analysis for DAWN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DAWN has been successfully added to your 
